Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M

PRECIGEN, INC.

50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.
40% ORR (2/5) and 60% DCR (3/5) in recurrent/metastatic HPV-associated cancer with PRGN-2009 AdenoVerse combination arm.
PRGN-3006 and PRGN-3005 show no dose-limiting toxicities or neurotoxicity; durable expansion and persistence observed.
Cash, equivalents, and investments totaled $181.3M at Sep 30, 2021; net cash used in ops $41.2M (9 months, vs $60.6M prior year).
PRGN-3006 abstract selected for oral presentation at 63rd ASH Annual Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.